A carregar...
Zanubrutinib Shows Clinical Benefits in Waldenström Macroglobulinemia
In the head‐to‐head phase III ASPEN trial, zanubrutinib showed clinically meaningful improvements in safety and tolerability versus ibrutinib, with comparable efficacy, in patients with Waldenström macroglobulinemia.
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330922/ https://ncbi.nlm.nih.gov/pubmed/32589334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0557 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|